Pharming Group N.V. (PHAR)

NGM – Real Time Price. Currency in USD

12.01

-0.22 (-1.80%)

Market open: Aug 12, 2026, 10:53 AM EDT

11.99

-0.24 (-1.96%)

Previous after-hours: Aug 11, 2026, 6:30 PM EDT

Stock details

Previous close: 12.23$
Day's range: 11.31 - 12.34$
52-week range: 9.62 - 21.34$
Volume: 89 776
Average volume: 29 233
Beta: 0.71
EPS (TTM): 0.13
PE ratio (TTM): 98.31
Forward P/E: 53.36
Market cap: 799 463 835
Shares outstanding: 65 369 079
Dividend yield: N/A
Next earnings date: 2026-11-05
Sector: Healthcare
Industry: Biotechnology

About the company

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an... read more

CEO: Fabrice Chouraqui
Country: Netherlands
IPO Date
Employees: 407
Fiscal Year End: January - December
Website: https://www.pharming.com

Revenue Breakdown

RUCONEST / 84.52%

Joenja / 15.48%

News

No Data

There are no news for this stock.

Chart: PHAR

Loading Chart...

Overall Score

4 / 1040%

Octagon View

Strength & Weakness

Company's cash reserves $158.3M significantly exceed its total debt $126.8M, ensuring strong financial flexibility

Total current assets $280.7M exceed Total current liabilities $93.2M, highlighting excellent liquidity

Debt-to-equity ratio (0.5) is well below the industry average (0.3), showcasing prudent financial management

Interest coverage ratio (0.7x) is dangerously low, suggesting debt repayment risks

Negative free cash flow -$12.8M limits the company's ability to reinvest or pay down debt

Financial Strength

NAME	RATIO	INDUSTRY	SCORE
Current ratio	3.01	6.05	10
Quick ratio	2.31	5.63	10
Debt to Equity	0.49	0.30	7.0
Debt to Assets	0.27	1.04	7.0
Interest coverage	0.74	-16.91	3.0
Weighted average score			7.4

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)

Values in USD (B=Billions, M=Millions, K=Thousands)

METRIC	2022	2023	2024	2025	TTM
Total Revenue	206M	246M	297M	377M	366M
Gross Profit	184M	209M	250M	321M	311M
Operating Income	4M	-22M	-4M	21M	22M
Net Income	14M	-11M	-12M	3M	9M
EBITDA	13M	-11M	7M	32M	34M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAME	RATIO	INDUSTRY	SCORE
Gross margin %	80.56	-11.73	10
Operating margin %	2.22	-24.60	2.0
Net margin %	1.77	-172.20	2.0
EBITDA margin %	5.59	-201.27	3.0
Cash flow margin %	-14.08	-156.39	1.0
Weighted average score			3.6

Net Margin

Effectiveness

NAME	RATIO	INDUSTRY	SCORE
ROA	1.39	-57.97	3.0
ROE	2.58	-63.56	3.0
ROIC	1.75	-42.57	4.0
ROCE	1.45	-71.10	3.0
Weighted average score			3.3

Estimated EPS vs Actual EPS

Forecast

NAME	REVENUE GROWTH	EPS GROWTH	SCORE
Current quarter	9	11.5	6.5
Next quarter	11.2	44.76	8.5
Current year	3.85	473	7.0
Next year	9.01	15.31	7.5
Weighted average score			7.4

Analyst Rating

Growth

NAME	REVENUE	NET INCOME	EPS	FCF	SCORE
Q/Q	23.88	130.54	128.57	-1019.65	7.8
Y/Y	-4.62	-65.71	-66.66	-203.87	1.0
3y average	22.45	-21.62	-20.19	211.44	5.5
5y average	12.95	-27.35	-27.63	107.9	5.0
Weighted average score					4.8

Revenue Growth Rate vs. Industry

Valuation

NAME	RATIO	INDUSTRY	SCORE
P/E	81.07	-5.25	3.0
PEG (5yr expected)	N/A	0.27	1.0
P/S	2.32	64.66	6.4
P/B	2.97	2.96	5.0
Weighted average score			3.9

DCF Model

DCF Model Period5 years

Discount rate8%

Perpetual growth rate3%

Revenue 5 year CAGR14.85%

FCF 5 year CAGR4

Fair value6.64$

Stock price12.0099$

Dividend

NAME	CURRENT	INDUSTRY	SCORE
Dividend yield	0.00	N/A	1.0
Payout ratio	0.00	N/A	1.0
5-year dividend growth rate	N/A	N/A	1.0
Years of dividend increase	N/A	N/A	1.0
Weighted average score			1.0

Fair Value

$6.64

UndervaluedStock priceOvervalued

$12.0099

Economic Moat

NAME	SCALE	SCORE
Market share	None	1.0
Intangible assets	None	1.0
Switching costs	None	1.0
Network effect	None	1.0
Economies of scale	None	1.0
Weighted average score		1.0

About the company

CEO

Fabrice Chouraqui

Country

Netherlands

IPO Date

Employees

407

Fiscal Year End

January - December

Website

https://www.pharming.com

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Current ratio

3.01

6.05

Quick ratio

2.31

5.63

Debt to Equity

0.49

0.30

7.0

Debt to Assets

0.27

1.04

7.0

Interest coverage

0.74

-16.91

3.0

Weighted average score

7.4

METRIC

2022

2023

2024

2025

TTM

Total Revenue

206M

246M

297M

377M

366M

Gross Profit

184M

209M

250M

321M

311M

Operating Income

-22M

-4M

21M

22M

Net Income

14M

-11M

-12M

EBITDA

13M

-11M

32M

34M

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Gross margin %

80.56

-11.73

Operating margin %

2.22

-24.60

2.0

Net margin %

1.77

-172.20

2.0

EBITDA margin %

5.59

-201.27

3.0

Cash flow margin %

-14.08

-156.39

1.0

Weighted average score

3.6

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

ROA

1.39

-57.97

3.0

ROE

2.58

-63.56

3.0

ROIC

1.75

-42.57

4.0

ROCE

1.45

-71.10

3.0

Weighted average score

3.3

NAME

REVENUE GROWTH

EPS GROWTH

SCORE

Current quarter

11.5

6.5

Next quarter

11.2

44.76

8.5

Current year

3.85

473

7.0

Next year

9.01

15.31

7.5

Weighted average score

7.4

NAME

REVENUE

NET INCOME

EPS

FCF

SCORE

Q/Q

23.88

130.54

128.57

-1019.65

7.8

Y/Y

-4.62

-65.71

-66.66

-203.87

1.0

3y average

22.45

-21.62

-20.19

211.44

5.5

5y average

12.95

-27.35

-27.63

107.9

5.0

Weighted average score

4.8

NAME

RATIO

INDUSTRY

5Q TREND

SCORE

P/E

81.07

-5.25

3.0

PEG (5yr expected)

N/A

0.27

1.0

P/S

2.32

64.66

6.4

P/B

2.97

2.96

5.0

Weighted average score

3.9

NAME

CURRENT

INDUSTRY

SCORE

Dividend yield

0.00

N/A

1.0

Payout ratio

0.00

N/A

1.0

5-year dividend growth rate

N/A

1.0

Years of dividend increase

N/A

1.0

Weighted average score

1.0

NAME

SCALE

SCORE

Market share

None

1.0

Intangible assets

None

1.0

Switching costs

None

1.0

Network effect

None

1.0

Economies of scale

None

1.0

Weighted average score

1.0

Search stocks

Pharming Group N.V. (PHAR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Pharming Group N.V. (PHAR)

Stock details

About the company

Revenue Breakdown

News

Chart: PHAR

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$6.64

$12.0099

Economic Moat

Stock details

About the company

Revenue Breakdown

News

Chart: PHAR

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$6.64

$12.0099

Economic Moat